{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:59:16Z","timestamp":1768683556392,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.bmcl.2020.126987","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T01:59:13Z","timestamp":1580090353000},"page":"126987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate"],"prefix":"10.1016","volume":"30","author":[{"given":"Iontcho R.","family":"Vlahov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longwu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari Krishna R.","family":"Santhapuram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Felten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garth L.","family":"Parham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy F.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer J.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna F.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2236-3999","authenticated-orcid":false,"given":"Paul J.","family":"Kleindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Reno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Nicoson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Leamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bmcl.2020.126987_h0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/cr00026a006","article-title":"Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines","volume":"94","author":"Thurston","year":"1994","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2020.126987_h0010","series-title":"Molecular Aspects of Anticancer Drug-DNA Interactions","first-page":"54","article-title":"Advances in the study of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor antibiotics","author":"Thurston","year":"1993"},{"issue":"24","key":"10.1016\/j.bmcl.2020.126987_h0015","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/ja00952a050","article-title":"Isolation and characterization of anthramycin, a new antitumor antibiotic","volume":"87","author":"Leimgruber","year":"1965","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2020.126987_h0020","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/199501a0","article-title":"'Refuin': A non-cytotoxic carcinostatic compound proliferated by a thermophilic actinomycete","volume":"199","author":"Tendler","year":"1963","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2020.126987_h0025","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PDB) \u2013 containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed"},{"issue":"4","key":"10.1016\/j.bmcl.2020.126987_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152303","article-title":"Covalent bonding of pyrrolobenzodiazepines (PBDs) to terminal guanine residues within duplex and hairpin DNA fragments","volume":"11","author":"Mantaj","year":"2016","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.bmcl.2020.126987_h0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105021","article-title":"Pyrrolobenzodiazepines (PBDs) do not bind to DNA G-quadruplexes","volume":"9","author":"Rahman","year":"2014","journal-title":"PLoS ONE"},{"issue":"46","key":"10.1016\/j.bmcl.2020.126987_h0040","doi-asserted-by":"crossref","first-page":"13593","DOI":"10.1021\/bi00250a011","article-title":"Crystal structure of a covalent DNA-drug adduct: anthramycin bound to C-C-A-A-C-G-T-T-G-G and a molecular explanation of specificity","volume":"33","author":"Kopka","year":"1994","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.bmcl.2020.126987_h0045","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.coph.2012.03.008","article-title":"Small molecule drugs \u2013 Optimizing DNA damaging agent-based therapeutics","volume":"12","author":"Hartley","year":"2012","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"10.1016\/j.bmcl.2020.126987_h0050","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin Invest Drugs"},{"issue":"4","key":"10.1016\/j.bmcl.2020.126987_h0055","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1021\/cr100120f","article-title":"Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)","volume":"111","author":"Antonow","year":"2011","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2020.126987_h0060","unstructured":"Vlahov, I. Q., L.; Hahn, S.; Wang, K.; Santhapuram, H.; Felten, A.; Vaughn, J.; Leamon, C. Design, synthesis and early evaluation of hybrids of DNA minor groove binders and DNA-alkylating agents as warheads for small molecule drug conjugates (SMDCs) for targeted cancer therapies. 2016, From Abstracts of Papers, 252nd ACS National Meeting & Exposition, Philadelphia, PA, United States, Philadelphia, PA, United States, August 21-26, MEDI-39."},{"issue":"302","key":"10.1016\/j.bmcl.2020.126987_h0065","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"issue":"7","key":"10.1016\/j.bmcl.2020.126987_h0070","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.bmcl.2020.126987_h0075","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev.nu.16.070196.002441","article-title":"Folate receptors","volume":"16","author":"Antony","year":"1996","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.bmcl.2020.126987_h0080","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrc3557","article-title":"Serine, glycine and one-carbon units: cancer metabolism in full circle","volume":"13","author":"Locasale","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.bmcl.2020.126987_h0085","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","article-title":"Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy","volume":"56","author":"Elnakat","year":"2004","journal-title":"Adv Drug Delivery Rev"},{"key":"10.1016\/j.bmcl.2020.126987_h0090","doi-asserted-by":"crossref","first-page":"584","DOI":"10.2119\/molmed.2015.00040","article-title":"Antiinflammatory activity of a novel folic acid targeted conjugate of the mTOR inhibitor everolimus","volume":"21","author":"Lu","year":"2015","journal-title":"Mol Med"},{"issue":"2","key":"10.1016\/j.bmcl.2020.126987_h0095","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ab.2004.12.026","article-title":"Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay","volume":"338","author":"Parker","year":"2005","journal-title":"Anal Biochem"},{"issue":"9","key":"10.1016\/j.bmcl.2020.126987_h0100","first-page":"2432","article-title":"Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines","volume":"73","author":"Ross","year":"1994","journal-title":"Physiol Clin implications Cancer"},{"issue":"12","key":"10.1016\/j.bmcl.2020.126987_h0105","first-page":"3396","article-title":"Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues","volume":"52","author":"Weitman","year":"1992","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.bmcl.2020.126987_h0110","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1097\/JTO.0b013e318267d051","article-title":"Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung","volume":"7","author":"Edelman","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.bmcl.2020.126987_h0115","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/annonc\/mdu024","article-title":"Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)","volume":"25","author":"Morris","year":"2014","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.bmcl.2020.126987_h0120","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1200\/JCO.2013.49.7685","article-title":"PRECEDENT: A randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer","volume":"31","author":"Naumann","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bmcl.2020.126987_h0125","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.1038\/s41598-018-27320-5","article-title":"Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic","volume":"8","author":"Reddy","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2020.126987_h0130","series-title":"Drug Delivery in Oncology","first-page":"1283","article-title":"Design and synthesis of drug conjugates of vitamins and growth factors","author":"Vlahov","year":"2012"},{"issue":"4","key":"10.1016\/j.bmcl.2020.126987_h0135","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.bmcl.2010.12.085","article-title":"Design and regioselective synthesis of a new generation of targeted therapeutics. Part 3: Folate conjugates of aminopterin hydrazide for the treatment of inflammation","volume":"21","author":"Vlahov","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"#cr-split#-10.1016\/j.bmcl.2020.126987_b0045.1","unstructured":"Spencer, S. D. Pyrrolobenzodiazepines and conjugates therof. 2013, US Patent 20130028917"},{"key":"#cr-split#-10.1016\/j.bmcl.2020.126987_b0045.2","unstructured":"Wilson, P. T. Compounds. 2000, WO00\/12507."},{"key":"#cr-split#-10.1016\/j.bmcl.2020.126987_b0045.3","unstructured":"(a) Howard, P. W.; Masterson, L.; Tiberghien, A. C.; Flygare, J. A.; Gunzer, J. L.; Polakis, P.; Polson, A.; Raab, H. E.; Spencer, S. D. Pyrrolobenzodiazepines and conjugates therof. 2013, US Patent 20130028917;"},{"key":"#cr-split#-10.1016\/j.bmcl.2020.126987_b0045.4","unstructured":"(b) Thurston, D. E.; Wilson, P. T. Compounds. 2000, WO00\/12507."},{"issue":"3","key":"10.1016\/j.bmcl.2020.126987_h0145","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjugate Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2020.126987_h0150","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bmcl.2005.09.081","article-title":"Dipeptide-based highly potent doxorubicin antibody conjugates","volume":"16","author":"Jeffrey","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"10.1016\/j.bmcl.2020.126987_b0055","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1021\/acs.bioconjchem.7b00476","article-title":"Latent warheads for targeted cancer therapy: design and synthesis of pro-pyrrolobenzodiazepines and conjugates","volume":"28","author":"Vlahov","year":"2017","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.bmcl.2020.126987_b0060","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1039\/CT9150701080","article-title":"The formation and stability of spiro-compounds. Part I. Spiro-compounds from cyclo-hexane","volume":"107","author":"Beesley","year":"1915","journal-title":"J Chem Soc Trans"},{"issue":"1","key":"10.1016\/j.bmcl.2020.126987_b0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10989-007-9078-z","article-title":"A novel oxazolidine linker for the synthesis of peptide aldehydes","volume":"13","author":"Tanaka","year":"2007","journal-title":"Int J Pept Res Ther"},{"issue":"19","key":"10.1016\/j.bmcl.2020.126987_b0070","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.bmcl.2006.07.030","article-title":"Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide","volume":"16","author":"Vlahov","year":"2006","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20300470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20300470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:32:57Z","timestamp":1760772777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X20300470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0960894X20300470"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.126987","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.126987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"126987"}}